{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:19:19Z","timestamp":1790216359261,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: The increasing prevalence of drug resistance in cancer therapy underscores the urgent need for novel therapeutic approaches. Dual enzyme inhibitors, targeting critical kinases such as CDK2 and TRKA, represent a promising strategy. The goal of this investigation was to design, synthesize, and evaluate a set of pyrazolo[1,5-a]pyrimidine derivatives for their dual inhibition potential toward CDK2 and TRKA kinases, along with their potential antiproliferative against cancer cell lines. Methods: A set of pyrazolo[1,5-a]pyrimidine derivatives (6a\u2013t, 11a\u2013g, and 12) was synthesized and subjected to in vitro enzymatic assays to determine their inhibitory activity against CDK2 and TRKA kinases. Selected compounds were further assessed for antiproliferative effects across the set of 60 cell lines from the NCI, representing various human cancer types. Additionally, simulations of molecular docking were conducted to explore the modes of binding for the whole active compounds and compare them with known inhibitors. Results: Compounds 6t and 6s exhibited potent dual inhibitory activity, showing an IC50 = 0.09 \u00b5M and 0.23 \u00b5M against CDK2, and 0.45 \u00b5M against TRKA, respectively. These results were comparable to reference inhibitors ribociclib (CDK2, IC50 = 0.07 \u00b5M) and larotrectinib (TRKA, IC50 = 0.07 \u00b5M). Among the studied derivatives, compound 6n displayed a notable broad-spectrum anticancer activity, achieving a mean growth inhibition (GI%) of 43.9% across 56 cell lines. Molecular docking simulations revealed that the synthesized compounds adopt modes of binding similar to those of the lead inhibitors. Conclusions: In this study, prepared pyrazolo[1,5-a]pyrimidine derivatives demonstrated significant potential as dual CDK2\/TRKA inhibitors, and showed potent anticancer activity toward diverse cancer cell lines. These findings highlight their potential as key compounds for the design of novel anticancer therapeutics.<\/jats:p>","DOI":"10.3390\/ph17121667","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:22:06Z","timestamp":1733833326000},"page":"1667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Design, Synthesis and Molecular Modeling of Pyrazolo[1,5-a]pyrimidine Derivatives as Dual Inhibitors of CDK2 and TRKA Kinases with Antiproliferative Activity"],"prefix":"10.3390","volume":"17","author":[{"given":"Mohamed H.","family":"Attia","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, October 6 University (O6U), Giza 12585, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-9757","authenticated-orcid":false,"given":"Deena S.","family":"Lasheen","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-5540","authenticated-orcid":false,"given":"Nermin","family":"Samir","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-2118","authenticated-orcid":false,"given":"Azza T.","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt"},{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, October 6 University (O6U), Giza 12585, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[{"name":"Department of Applied Organic Chemistry, National Research Center, Cairo 12622, Egypt"},{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia St., Alexandria 21648, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal A.","family":"Abou El Ella","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014The major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of Selective Kinase Inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The Protein Kinase Complement of the Human Genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112025","DOI":"10.1016\/j.ejmech.2019.112025","article-title":"Dual-target kinase drug design: Current strategies and future directions in cancer therapy","volume":"188","author":"Sun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biol., 15.","DOI":"10.1186\/gb4184"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1242\/dev.091744","article-title":"Cdks, cyclins and CKIs: Roles beyond cell cycle regulation","volume":"140","author":"Lim","year":"2013","journal-title":"Development"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35226","DOI":"10.18632\/oncotarget.26215","article-title":"The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml100051d","article-title":"Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases","volume":"1","author":"Paruch","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrn1078","article-title":"Neurotrophins and their receptors: A convergence point for many signalling pathways","volume":"4","author":"Chao","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk Receptors: Roles in Neuronal Signal Transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing Down an Old Oncogene in a New Era of Targeted Therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: A bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cels.2018.10.006","article-title":"The Min Oscillator Defines Sites of Asymmetric Cell Division in Cyanobacteria during Stress Recovery","volume":"7","author":"Liao","year":"2018","journal-title":"Cell Syst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Metwally, N.H., Deeb, E.A., and Hasani, I.W. (2024). Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4\u2032,3\u2032:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors. BMC Chem., 18.","DOI":"10.1186\/s13065-024-01166-7"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Almehmadi, S.J., Alsaedi, A.M.R., Harras, M.F., and Farghaly, T.A. (2021). Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia. Bioorg. Chem., 117.","DOI":"10.1016\/j.bioorg.2021.105431"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1021\/jm9006559","article-title":"Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1 H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor","volume":"52","author":"Brasca","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, Y., Zhou, Y., Zhang, Q., Han, T., Tang, C., and Fan, W. (2021). Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation. Bioorg. Med. Chem. Lett., 31.","DOI":"10.1016\/j.bmcl.2020.127712"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cmdc.200600302","article-title":"6-Substituted Pyrrolo[3,4-c]pyrazoles: An Improved Class of CDK2 Inhibitors","volume":"2","author":"Brasca","year":"2007","journal-title":"ChemMedChem"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2019.01.008","article-title":"Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity","volume":"86","author":"Ali","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10285","DOI":"10.1039\/C5RA27017K","article-title":"Design and synthesis of potent N-phenylpyrimidine derivatives for the treatment of skin cancer","volume":"6","author":"Chaube","year":"2016","journal-title":"RSC Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13024","DOI":"10.1016\/j.tet.2007.10.014","article-title":"A highly efficient regioselective one-pot synthesis of 2,3,6-trisubstituted pyridines and 2,7,7-trisubstituted tetrahydroquinolin-5-ones using K5CoW12O40\u00b73H2O as a heterogeneous recyclable catalyst","volume":"63","author":"Kantevari","year":"2007","journal-title":"Tetrahedron"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.bmcl.2016.05.019","article-title":"Synthesis and biological evaluation of oxindole linked indolyl-pyrimidine derivatives as potential cytotoxic agents","volume":"26","author":"Prajapti","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.3390\/molecules181113645","article-title":"Clean and Efficient Synthesis of Isoxazole Derivatives in Aqueous Media","volume":"18","author":"Dou","year":"2013","journal-title":"Molecules"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/cbdd.13019","article-title":"Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor","volume":"90","author":"Zhou","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112019","DOI":"10.1016\/j.ejmech.2019.112019","article-title":"Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation","volume":"189","author":"Said","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jangid, D.K., and Dhadda, S. (2020). Phenacyl Bromide: An Organic Intermediate for Synthesis of Five- and Six-Membered Bioactive Heterocycles. Heterocycles\u2014Synthesis and Biological Activities, IntechOpen.","DOI":"10.5772\/intechopen.88243"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1039\/C7NJ00052A","article-title":"Supporting Information for A New and Versatile One-Pot Strategy to synthesize alpha-Bromoketones from Secondary Alcohols Using Ammonium Bromide and Oxone","volume":"41","author":"Rammurthy","year":"2017","journal-title":"New J. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1039\/C7GC00283A","article-title":"Water-controlled selective preparation of \u03b1-mono or \u03b1,\u03b1\u2032-dihalo ketones via catalytic cascade reaction of unactivated alkynes with 1,3-dihalo-5,5-dimethylhydantoin","volume":"19","author":"Wu","year":"2017","journal-title":"Green Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"o2245","DOI":"10.1107\/S1600536809033303","article-title":"2-Bromo-1-(4-methoxyphenyl)ethenone","volume":"65","author":"Zhang","year":"2009","journal-title":"Acta Crystallogr. Sect. E Struct. Rep. Online"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-1997-1186","article-title":"Steric and Electronic Control in the Addition of Hydrazine and Phenylhydrazine to \u03b1-[(Dimethylamino)methylene]-\u03b2-oxoarylpropanenitriles","volume":"1997","author":"Tupper","year":"1997","journal-title":"Synthesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.bmc.2007.10.079","article-title":"Synthesis of fluorine substituted pyrazolopyrimidines as potential leads for the development of PET-imaging agents for the GABAA receptors","volume":"16","author":"Hoepping","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/molecules14010078","article-title":"Synthesis of 5-Substituted 3-Amino-1H-Pyrazole-4-Carbonitriles as Precursors for Microwave Assisted Regiospecific Syntheses of Pyrazolo[1,5-a]Pyrimidines","volume":"14","author":"Mandani","year":"2008","journal-title":"Molecules"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"463515","DOI":"10.1155\/2013\/463515","article-title":"A Facile Synthesis of Pyrido[2\u2032,3\u2032:3,4]pyrazolo[1,5-a]pyrimidine and Pyrido[2\u2032,3\u2032:3,4]pyrazolo[5,1-c][1,2,4]triazine Bearing a Thiophene Moiety","volume":"2013","author":"Elsaman","year":"2013","journal-title":"J. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sobhy, M.K., Mowafy, S., Lasheen, D.S., Farag, N.A., and Abouzid, K.A.M. (2019). 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. Bioorg. Chem., 89.","DOI":"10.1016\/j.bioorg.2019.102988"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1021\/acschembio.5b00398","article-title":"Type II Inhibitors Targeting CDK2","volume":"10","author":"Alexander","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mohammad, T., Batra, S., Dahiya, R., Baig, M.H., Rather, I.A., Dong, J.-J., and Hassan, I. (2019). Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy. Molecules, 24.","DOI":"10.3390\/molecules24244589"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1021\/cb4003283","article-title":"Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains","volume":"8","author":"Martin","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: A webserver for the prediction of toxicity of chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1900383","DOI":"10.1002\/ardp.201900383","article-title":"Sulfonamides incorporating ketene N,S-acetal bioisosteres as potent carbonic anhydrase and acetylcholinesterase inhibitors","volume":"353","author":"Istrefi","year":"2020","journal-title":"Arch. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/00397910701473317","article-title":"Novel Cyanoketene N,S-Acetals and Pyrazole Derivatives using Potassium 2-Cyanoethylene-1-thiolates","volume":"37","author":"Elgemeie","year":"2007","journal-title":"Synth. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0040-4020(01)85083-3","article-title":"A Convenient Alternative Route to f3-Aminoketones","volume":"50","author":"Sanmardn","year":"1994","journal-title":"Tetrahedron"},{"key":"ref_44","first-page":"589","article-title":"Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay","volume":"48","author":"Alley","year":"1988","journal-title":"Cancer Res."},{"key":"ref_45","first-page":"622","article-title":"The National Cancer Institute: Cancer drug discovery and development program","volume":"19","author":"Grever","year":"1992","journal-title":"Semin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lange, A., and Lo, H.-W. (2018). Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers, 10.","DOI":"10.3390\/cancers10040105"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","article-title":"A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry","volume":"139","author":"Nicoletti","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:49Z","timestamp":1760115109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121667"],"URL":"https:\/\/doi.org\/10.3390\/ph17121667","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}